Latest Healthcare Sector News

AuMake Limited reports positive operating cashflow and a strategic pivot into China’s high-growth OTC medicine market, supported by a $1.5 million capital raise and significant governance reforms.

Next Science Limited has updated the payment date for its cash return of capital to 10 February 2026, following its recent asset sale and pending ASX delisting.

333D Ltd reports continued revenue growth in digital asset management and unveils a pioneering blockchain solution for MRI data storage, reinforcing its foothold in digital healthcare.

Constellation Technologies has broadened its IoT deployments into defence and healthcare sectors while improving its cash flow position in the December quarter.

ReNerve Limited reported a robust 80% increase in quarterly sales driven by strong US market adoption and expanded hospital approvals. The company advances its nerve repair product pipeline with key regulatory milestones and a refreshed board.

Holista Colltech has reported a positive operating cash flow for the December quarter, driven by disciplined cost management and a successful capital raise, despite softer sales and ongoing legal disputes.

PainChek has secured FDA De Novo clearance, enabling entry into the vast US healthcare market with a $3 billion Remote Therapeutic Monitoring opportunity. The company reports $5.6 million contracted ARR and a strong global footprint in aged care.

Inhalerx Limited reported a $628,000 cash burn in the December quarter while securing substantial funding facilities to advance its clinical trials. The company’s cash position and financing arrangements suggest a runway extending over 80 quarters at current spending levels.

ECS Botanics Holdings Ltd has seen its ECSO securities suspended from ASX quotation due to non-compliance with listing rules, raising questions about the company’s next steps.

Wellnex Life reports a significant turnaround with a 31.5% revenue increase and near break-even operating cash flow in the December quarter, driven by strategic brand consolidation and cost discipline.

Freedom Care Group Holdings reports a modest cash increase to $0.5 million but continues to grapple with delayed payments from the NDIA, while exploring options to relist on the ASX.

Freedom Care Group Holdings has revealed ongoing financial distress with key subsidiaries entering liquidation and persistent delays in payments from the NDIA, leaving the company with a diminished cash reserve and a strategic focus on asset sales and cost reduction.